Elevated serum creatinine levels associated with fenofibrate therapy.
OBJECTIVE
The case of a patient who developed clinically relevant increases in serum creatinine (SCr) levels while receiving fenofibrate therapy is reported.


CONCLUSIONS
Fenofibrate therapy was initiated for a 60-year old Hispanic man with stage 4 chronic kidney disease (CKD) for the treatment of hypertriglyceridemia. Two weeks after taking 48 mg of fenofibrate daily, the patient's SCr and blood urea nitrogen concentrations increased from 3.0 and 25 mg/dL, respectively, to 3.5 and 30 mg/dL, respectively. His estimated glomerular filtration rate (eGFR) had decreased from 24.8 to 17.9 mL/min/1.73 m(2). One month after initiating fenofibrate, his SCr concentration had increased to 3.7 mg/dL, a 32% increase from baseline. Because of persistently high triglyceride concentrations (e.g., 402 mg/dL), the fenofibrate dosage was increased to 145 mg daily. The patient's SCr concentration rose to 4.7 mg/dL (a 62% increase from baseline), and his eGFR was calculated as 13 mL/min/1.73 m(2). The patient was referred by the nephrology service for vascular-access placement in preparation for hemodialysis. Four days after discontinuation of fenofibrate, the patient's SCr concentration dropped to 3.3 mg/dL and returned to baseline approximately six weeks later, with an eGFR of 20.5 mL/min/1.73 m(2). Preparation for hemodialysis was terminated, and the patient's eGFR remained stable at 20.2 mL/min/1.73 m(2) for the 12 months after fenofibrate discontinuation. A score of 4 on the Naranjo et al. probability scale indicated that there was a possible association between fenofibrate and renal dysfunction in this patient.


CONCLUSIONS
A 60-year-old patient developed renal impairment after receiving fenofibrate for the treatment of hypertriglyceridemia.
McQuade
Charles R
CR
University of New Mexico College of Pharmacy, Albuquerque, NM 87131, USA.
Griego
Jennifer
J
Anderson
Joe
J
Pai
Amy Barton
AB
D002908:Chronic Disease; D003404:Creatinine / Q000097:blood*; D011345:Fenofibrate / Q000009:adverse effects*; D006801:Humans; D015228:Hypertriglyceridemia / Q000097:blood / Q000188:drug therapy*; D000960:Hypolipidemic Agents / Q000009:adverse effects*; D007674:Kidney Diseases / Q000097:blood / Q000139:chemically induced* / Q000188:drug therapy; D008297:Male; D008875:Middle Aged
D000960:Hypolipidemic Agents; D003404:Creatinine; D011345:Fenofibrate